Compare DAO & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAO | INBX |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2019 | 2024 |
| Metric | DAO | INBX |
|---|---|---|
| Price | $15.15 | $98.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $17.58 | ★ $266.67 |
| AVG Volume (30 Days) | 47.1K | ★ 282.4K |
| Earning Date | 11-19-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $8.23 | N/A |
| Revenue Next Year | $14.68 | N/A |
| P/E Ratio | $72.35 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $8.38 | $28.16 |
| 52 Week High | $18.94 | $155.29 |
| Indicator | DAO | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 43.08 |
| Support Level | $9.43 | $96.60 |
| Resistance Level | $18.79 | $106.40 |
| Average True Range (ATR) | 0.67 | 5.75 |
| MACD | 0.10 | -1.44 |
| Stochastic Oscillator | 67.90 | 11.13 |
Youdao Inc develops and markets software applications. It engages in developing technologies to provide learning content, applications, and solutions. The firm operates in three segments: Learning services, Smart devices, and Online marketing services. The majority of its revenue comes from the Learning services segment, which generates revenues from online courses, mainly including Youdao Premium Courses, NetEase Cloud Classroom, and China University MOOC. The learning products segment includes sales of smart devices such as the Youdao Dictionary Pen and the Youdao Pocket Translator. Geographically, all of its revenue is generated from the People's Republic of China.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.